MY165097A - Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm - Google Patents

Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Info

Publication number
MY165097A
MY165097A MYPI2013004204A MYPI2013004204A MY165097A MY 165097 A MY165097 A MY 165097A MY PI2013004204 A MYPI2013004204 A MY PI2013004204A MY PI2013004204 A MYPI2013004204 A MY PI2013004204A MY 165097 A MY165097 A MY 165097A
Authority
MY
Malaysia
Prior art keywords
combination
treatment
ruxolitinib
panobinostat
cancer
Prior art date
Application number
MYPI2013004204A
Inventor
Fabienne Baffert
Thomas Radimerski
Brian Gadbaw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY165097A publication Critical patent/MY165097A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE INVENTION RELATES TO A COMBINATION WHICH COMPRISES: (A) COMPOUND A ((R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE) OF FORMULA (A): OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AND (B) COMPOUND B (N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)-ETHYL]-AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE) OF FORMULA (B): OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FOR SIMULTANEOUS, CONCURRENT, SEPARATE OR SEQUENTIAL USE, ESPECIALLY FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES. THE INVENTION ALSO RELATES TO PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH A COMBINATION AND TO A METHOD OF TREATING PROLIFERATIVE DISEASES, IN A MAMMAL, PARTICULARLY A HUMAN, WITH SUCH A COMBINATION. THE PRESENT INVENTION FURTHER ALSO RELATES TO A COMMERCIAL PACKAGE OR PRODUCT COMPRISING SUCH A COMBINATION.
MYPI2013004204A 2011-06-14 2012-06-13 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm MY165097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496750P 2011-06-14 2011-06-14
US201161568717P 2011-12-09 2011-12-09
US201261644153P 2012-05-08 2012-05-08

Publications (1)

Publication Number Publication Date
MY165097A true MY165097A (en) 2018-02-28

Family

ID=62165220

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013004204A MY165097A (en) 2011-06-14 2012-06-13 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Country Status (1)

Country Link
MY (1) MY165097A (en)

Similar Documents

Publication Publication Date Title
SG195141A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
EA033689B9 (en) Inhibitors of kras g12c
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
TN2009000344A1 (en) Combinations of therapeutic agents for treating cancer
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
EA201071094A1 (en) TRIPLE-substituted 1,2,4-TRIAZOLES AS MODULATORS OF NICOTINE ACETYL-HOLINE RECEPTORS
DK2324008T3 (en) Diarylpyrazole as protein kinase inhibitors
EA201100030A1 (en) PYRAZOL COMPOUNDS 436
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
EA201201680A1 (en) MORFOLINOPYRIMIDINES AND THEIR APPLICATION IN THERAPY
MX2013008296A (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
EA201391263A1 (en) COMBINED THERAPIES OF HEMATOLOGICAL TUMORS
EA201071288A1 (en) TRIPLE PYRAZOLES AS MODULATORS OF ACETYLCHOLINE RECEPTORS
TW200616953A (en) Indole, indazole or indoline derivatives
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2014006004A (en) N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy.
AR085173A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES
MX2016004936A (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives, pharmaceutical compositions containing them, and their use in therapy.
EA201390984A1 (en) HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
PH12014501495A1 (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
MY172729A (en) Pharmaceutical formulations
MX2015000746A (en) Combination therapy of inhibitors for igf1 r and pi3k.
IN2015DN00528A (en)
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors